Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/ tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer

H. Taniguchi,Y. Kuboki,J. Watanabe, T. Terazawa,H. Kawakami, M. Yokota,M. Nakamura,M. Kotaka,N. Sugimoto,H. Ojima,E. Oki,T. Kajiwara, T. Moriwaki,T. Takayama, T. Denda, T. Tamura,Y. Sunakawa, S. Ishihara,T. Nakajima,S. Morita, K. Shirao, T. Yoshino

ANNALS OF ONCOLOGY(2022)

引用 0|浏览26
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要